CA2464947A1 - Combination therapy for treating disease - Google Patents
Combination therapy for treating disease Download PDFInfo
- Publication number
- CA2464947A1 CA2464947A1 CA002464947A CA2464947A CA2464947A1 CA 2464947 A1 CA2464947 A1 CA 2464947A1 CA 002464947 A CA002464947 A CA 002464947A CA 2464947 A CA2464947 A CA 2464947A CA 2464947 A1 CA2464947 A1 CA 2464947A1
- Authority
- CA
- Canada
- Prior art keywords
- alt
- monoclonal antibody
- chemotherapeutic drug
- administered
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002648 combination therapy Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 40
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 19
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract 19
- 206010028980 Neoplasm Diseases 0.000 claims abstract 14
- 239000000427 antigen Substances 0.000 claims abstract 14
- 102000036639 antigens Human genes 0.000 claims abstract 14
- 108091007433 antigens Proteins 0.000 claims abstract 14
- 201000011510 cancer Diseases 0.000 claims abstract 11
- 239000011230 binding agent Substances 0.000 claims abstract 9
- 230000005745 host immune response Effects 0.000 claims abstract 9
- 238000001727 in vivo Methods 0.000 claims abstract 3
- 230000001939 inductive effect Effects 0.000 claims abstract 3
- 241001529936 Murinae Species 0.000 claims 4
- 230000000973 chemotherapeutic effect Effects 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229940125645 monoclonal antibody drug Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pregnancy & Childbirth (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Disclosed are methods for treating cancer comprising administering a xenotypic monoclonal antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen in present in the host serum, which antigen does not elicit a host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein a host immune response is elicited against a second epitope on the antigen.
Claims (37)
1. A method for treating cancer, comprising concurrently administering xenotypic monoclonal antibody and a chemotherapeutic drug to a patient suffering from cancer.
2. The method of claim 1, wherein the xenotypic monoclonal antibody is murine.
3. The method of claim 2, wherein the antibody is selected from the group consisting of Alt-1, Alt-2, Alt-3, Alt-4, Alt-5, and Alt-6.
4. The method of claim 1, wherein the patient is human.
5. The method of claim 1 or 3, wherein the chemotherapeutic is administered within a week before the murine monoclonal antibody.
6. The method of claim for 3 wherein, the chemotherapeutic is administered within a week after the monoclonal antibody.
7. The method of claim 1 or 3, wherein the antibody is administered in a dose of less than or equal to 2mg.
8. The method of claim 2, further comprising surgical removal of the cancer.
9. A method for treating cancer, comprising surgical removal of the cancer, concurrent administration of a chemotherapeutic drug and administration of a xenotypic monoclonal antibody in a dose equal to or less than 2mg.
10. The method of claim 9 wherein the monoclonal antibody is selected from the group consisting of Alt-1, Alt-2, Alt-3, Alt-4, Alt-5, and Alt-6.
11. The method of claim 9 wherein the administration of the antibody is over a minute intravenous infusion.
12. The method of claim 9 wherein the chemotherapeutic drug is administered within seven days prior to the administration of the monoclonal antibody.
13. The method of claim 9 wherein the chemotherapeutic drug is administered within seven days following the administration of the monoclonal antibody.
14. The method of claim 12 or 13 wherein the chemotherapeutic drug is administered every four weeks for six cycles.
15. The method of claim 14 wherein the method further comprises the step of administration of the xenotypic monoclonal antibody every twelve weeks for up to two years.
16. The method of claim 15 wherein the xenotypic monoclonal antibody and chemotherapeutic drug are administered on weeks 1, 4, and 8, followed by further administration of the chemotherapeutic drug alone on weeks 12 and 16, followed by concurrent administration of the chemotherapeutic drug and xenotypic monoclonal antibody on week 20.
17. The method of claim 9 wherein the concurrent administration of the xenotypic monoclonal antibody and the chemotherapeutic drug occurs on week 1, followed by administration of the chemotherapeutic drug on week 4, repeated for six cycles and followed by administration of the xenotypic monoclonal antibody every twelve weeks for up to two years.
18. A method for treating cancer in a patient, comprising surgical removal of the cancer, administration of a xenotypic monoclonal antibody on weeks 1, 3, 5, 7 and 9 followed by concurrent administration of a chemotherapeutic drug and a xenotypic monoclonal antibody in a dose less than or equal to 2mg on week 12.
19. The method of claim 13 wherein the concurrent administration of the chemotherapeutic drug and xenotypic monoclonal antibody is repeated every four weeks for up to 6 cycles.
20. The method of claim 14 further comprising the step of administering the xenotypic monoclonal antibody every twelve weeks for up to two years.
21. The method of claim 11 wherein the monoclonal antibody is selected from the group consisting of Alt-1, Alt-2, Alt-3, Alt-4, Alt-5, and Alt-6.
22. A method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen, which antigen does not elicit an effective host immune response, comprising concurrently administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agendantigen pair, wherein a host immune response is elicited against a second epitope on the antigen.
23. The method of claim 22 wherein the xenotypic monoclonal antibody is murine.
24. The method of claim 23, wherein the antibody is selected from the group consisting of Alt-1, Alt-2, Alt-3, Alt-4, Alt-5, and Alt-6.
25. The method of claim 22, wherein the patient is human.
26. The method of claim 22, wherein the chemotherapeutic drug is administered within a week before the murine monoclonal antibody.
27. The method of claim 22, wherein the chemotherapeutic drug is administered within a week after the monoclonal antibody.
28. The method of claim 22, wherein the antibody is administered in a dose of equal to or less than 2mg.
29. The method of claim 22, further comprising surgical removal of the cancer.
30. A method for treating cancer, comprising concurrent administration of a chemotherapeutic drug, a binding agent, and an antigen.
31. The method of claim 30, wherein the binding agent is a marine monoclonal antibody.
32. The method of claim 30, wherein the antibody is selected from the group consisting of Alt-1, Alt-2, Alt-3, Alt-4, Alt-5, and Alt-6.
33. The method of claim 30, wherein the patient is human.
34. The method of claim 31, wherein the chemotherapeutic is administered within a week before the marine monoclonal antibody.
35. The method of claim 31 wherein, the chemotherapeutic is administered within a week after the monoclonal antibody.
36. The method of claim 31, wherein the antibody is administered in a dose of equal to or less than 2mg.
37. A method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen, which antigen does not elicit an effective host immune response, comprising concurrently administering to the patient a chemotherapeutic drug and a composition comprising a binding agent present in an amount of from 0.1 µg to 2mg per kg of body weight of the host, and wherein the binding agent specifically binds to an epitope on the antigen and an effective host immune response is elicited against a second epitope on the antigen.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33924001P | 2001-10-26 | 2001-10-26 | |
| US60/339,240 | 2001-10-26 | ||
| PCT/IB2002/005794 WO2003034977A2 (en) | 2001-10-26 | 2002-10-28 | Combination therapy for treating disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2464947A1 true CA2464947A1 (en) | 2003-05-01 |
| CA2464947C CA2464947C (en) | 2012-05-22 |
Family
ID=23328122
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2464947A Expired - Lifetime CA2464947C (en) | 2001-10-26 | 2002-10-28 | Combination therapy for treating disease |
Country Status (9)
| Country | Link |
|---|---|
| AT (1) | AT500649A1 (en) |
| AU (1) | AU2002358246B2 (en) |
| CA (1) | CA2464947C (en) |
| CH (1) | CH696871A5 (en) |
| DE (1) | DE10297379T5 (en) |
| ES (1) | ES2304264A1 (en) |
| GB (1) | GB2397018B (en) |
| NO (1) | NO20042166L (en) |
| WO (1) | WO2003034977A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8038994B2 (en) | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| WO2008091643A2 (en) * | 2007-01-23 | 2008-07-31 | Altarex Medical Corp. | In vitro culture system to evaluate synergy in targeting immune suppressive pathways concurrent to immunotherapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6997394A (en) * | 1993-05-27 | 1994-12-20 | Harald Schlebusch | Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them |
| NZ332588A (en) * | 1996-05-15 | 2000-11-24 | Altarex Inc | Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer |
| AU784045B2 (en) * | 1999-06-25 | 2006-01-19 | Genentech Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP1198251B1 (en) * | 1999-07-23 | 2006-11-29 | Glaxo Group Limited | Combination of an anti-ep-cam antibody with a chemotherapeutic agent |
| JP2003519096A (en) * | 1999-08-18 | 2003-06-17 | アルタレックス コーポレーション | Therapeutic antibodies to MUC-1 antigen and methods of using the same |
| US6627196B1 (en) * | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
| ATE360212T1 (en) * | 2000-02-08 | 2007-05-15 | Altarex Medical Corp | METHOD FOR DIAGNOSING THE EFFECTIVENESS OF XENOTYPIC ANTIBODIES THERAPY |
| GB2390811B (en) * | 2001-03-21 | 2006-01-18 | Altarex Inc | Therapeutic compositions that alter the immune response |
-
2002
- 2002-10-28 GB GB0409191A patent/GB2397018B/en not_active Expired - Fee Related
- 2002-10-28 AU AU2002358246A patent/AU2002358246B2/en not_active Ceased
- 2002-10-28 WO PCT/IB2002/005794 patent/WO2003034977A2/en not_active Application Discontinuation
- 2002-10-28 CH CH00729/04A patent/CH696871A5/en not_active IP Right Cessation
- 2002-10-28 CA CA2464947A patent/CA2464947C/en not_active Expired - Lifetime
- 2002-10-28 ES ES200450028A patent/ES2304264A1/en active Pending
- 2002-10-28 AT AT0923902A patent/AT500649A1/en not_active Application Discontinuation
- 2002-10-28 DE DE10297379T patent/DE10297379T5/en not_active Withdrawn
-
2004
- 2004-05-25 NO NO20042166A patent/NO20042166L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AT500649A1 (en) | 2006-02-15 |
| NO20042166L (en) | 2004-05-25 |
| CH696871A5 (en) | 2008-01-15 |
| GB2397018B (en) | 2006-05-31 |
| WO2003034977A2 (en) | 2003-05-01 |
| CA2464947C (en) | 2012-05-22 |
| ES2304264A1 (en) | 2008-10-01 |
| GB2397018A (en) | 2004-07-14 |
| AU2002358246B2 (en) | 2008-02-28 |
| GB0409191D0 (en) | 2004-05-26 |
| DE10297379T5 (en) | 2004-10-14 |
| WO2003034977A3 (en) | 2004-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU96101193A (en) | ANTIBODY FRAGMENTS IN THERAPY | |
| JP2004501101A5 (en) | ||
| WO1985000974A1 (en) | Antibody compositions of therapeutic agents having an extended serum half-life | |
| JPH01275535A (en) | Suppression of response of b-lymphocyte in mammal | |
| JP2003517461A5 (en) | ||
| JP2003519096A5 (en) | ||
| JPH07316074A (en) | Combination of substance inducing necrosis with substance activated by necrosis,that is used for selectively curing tumor and inflammatory disease | |
| EP1684770B1 (en) | Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer | |
| WO1992007466A1 (en) | Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents | |
| EP2563815A2 (en) | Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy | |
| WO1995024927A1 (en) | Immunotherapeutic method of treating cancerous diseases by administration of gamma globulins | |
| US20230149347A1 (en) | CXCR4/CXCR7 Blockade and Treatment of Human Papilloma Virus-Associated Disease | |
| CA2464947A1 (en) | Combination therapy for treating disease | |
| JP2005529152A5 (en) | ||
| WO2002087611A2 (en) | Agent of human origin for vaccination against gd2 positive tumours | |
| AU719074B2 (en) | Combination of temozolomide and alpha-IFN for the treatment of advanced cancer | |
| Ferrer et al. | Prevention of therapeutically induced regression of sarcoma 180 by immunologic enhancement | |
| US6231855B1 (en) | Monoclonal antibodies as antidotes for anthracycline antibiotics | |
| CN110151987B (en) | Application of symmetrical IgG and composition thereof in preparation of medicines for treating and preventing tumors | |
| JP2002506051A (en) | Radioimmunoagent for treating HIV-1 infection | |
| AU2005211669B2 (en) | Treatment of intermediate- and high-grade non-Hodgkins lymphoma with anti-CD20 antibody | |
| EP0503484B1 (en) | Monoclonal antibodies as antidotes | |
| RU2531049C2 (en) | Therapeutic agent for treating prostatic diseases and method of treating prostatic diseases | |
| RU2197990C2 (en) | Method for treating sepsis-suffering patients | |
| Beauvais et al. | Improvement of cytomegalovirus-related Guillain-Barré syndrome after high doses of intravenous methylprednisolone pulses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20221028 |